Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Niagen Bioscience (NAGE) Other Operating Expenses (2016 - 2025)

Niagen Bioscience (NAGE) has disclosed Other Operating Expenses for 15 consecutive years, with $8.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Operating Expenses fell 3.27% to $8.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $33.5 million, a 13.76% increase, with the full-year FY2025 number at $33.5 million, up 13.76% from a year prior.
  • Other Operating Expenses was $8.4 million for Q4 2025 at Niagen Bioscience, down from $8.8 million in the prior quarter.
  • In the past five years, Other Operating Expenses ranged from a high of $8.8 million in Q3 2025 to a low of $5.9 million in Q3 2022.
  • A 5-year average of $7.3 million and a median of $7.1 million in 2021 define the central range for Other Operating Expenses.
  • Peak YoY movement for Other Operating Expenses: surged 40.72% in 2021, then dropped 28.4% in 2022.
  • Niagen Bioscience's Other Operating Expenses stood at $8.6 million in 2021, then decreased by 28.4% to $6.2 million in 2022, then grew by 5.38% to $6.5 million in 2023, then soared by 33.68% to $8.7 million in 2024, then fell by 3.27% to $8.4 million in 2025.
  • Per Business Quant, the three most recent readings for NAGE's Other Operating Expenses are $8.4 million (Q4 2025), $8.8 million (Q3 2025), and $8.2 million (Q2 2025).